Efficacy of antidepressants: bias in randomized clinical trials and related issues
The DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index.
Abstract
Introduction Countless antidepressant randomized trials were conducted and showed statistically significant benefits of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) over placebo. Meanwhile, critics are increasing regarding the efficacy of antidepressants in the treatment of MDD because at least a proportion of clinical trials could be hampered by various biases. In contrast, number of failed trials is increasing in the recent years which have made developing psychiatric medications progressively more time-consuming and expensive. Areas covered: Biases and related issues in clinical trials for antidepressants can be identified as an important common contributing factor to the two paradoxical phenomenon. This review identifies possible biases that can occur before, during, and after clinical trials of antidepressant. Expert commentary: Recent studies not only may over-estimate efficacy of antidepressants, but also may exaggerate placebo response because of various biases. Sponsorship and publication biases have been one of the targets of the criticism and ethical debate. Thus, initiating new trend of research by re-organizing academic-industry partnership will be the most important task in the next five years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although SSRIs and serotonin-norepinephrine reuptake inhibitor (SNRIs) perform better than placebo at reducing symptoms of depression188, 189, there are weeks-long lag time in attaining full benefit and many patients do not respond.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [188]
In the citing paper
“Although SSRIs and serotonin-norepinephrine reuptake inhibitor (SNRIs) perform better than placebo at reducing symptoms of depression188, 189, there are weeks-long lag time in attaining full benefit and many patients do not respond.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [188]
In the citing paper
“Although SSRIs and serotonin-norepinephrine reuptake inhibitor (SNRIs) perform better than placebo at reducing symptoms of depression188, 189, there are weeks-long lag time in attaining full benefit and many patients do not respond.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [188]
In the citing paper
“Various biases could have resulted in discrepancies between results from RCT and naturalistic studies.”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [105]
Citations
Cites
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634 · cited 1×
“showed that inadequate allocation concealment can exaggerate the estimate of the effect size of interventions up to 40% [19].”
BackgroundKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442 · cited 2×
“placebo in treating mild-to-moderate depression [8,20].”
BackgroundSelective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 2×
“Publication of antidepressant trials suggesting publication bias from [46], adapted from [1].”
BackgroundAntidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Regression to the mean: what it is and how to deal with it
Barnett, A. G. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh299 · Cited by 1,988 · cited 1×
“One important related bias is called regression to the mean, which is a statistical phenomenon stating that data that are extremely higher or lower than the mean will likely be closer to the mean if it is measured a second time [74].”
BackgroundThe Hawthorne Effect: a randomised, controlled trial
McCarney, R., Warner, J., Iliffe, S., van Haselen, R., Griffin, M., & Fisher, P. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-30 · Cited by 1,715
Language bias in randomised controlled trials published in English and German
Egger, M., Zellweger-Zähner, T., Schneider, M., Junker, C., Lengeler, C., & Antes, G. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02419-7 · Cited by 1,028
D'Agostino, R. B., Massaro, J. M., & Sullivan, L. M. (2003) · Statistics in Medicine · doi:10.1002/sim.1425 · Cited by 715
The Placebo Effect: Dissolving the Expectancy Versus Conditioning Debate.
Stewart-Williams, S., & Podd, J. (2004) · Psychological Bulletin · doi:10.1037/0033-2909.130.2.324 · Cited by 664
Statistical Considerations in the Intent-to-Treat Principle
Lachin, J. M. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00046-5 · Cited by 652 · cited 1×
“evaluation on the basis of the ITT a subject rather than the actual treatment given [32].”
BackgroundThe method of minimization for allocation to clinical trials
Scott, N. W., McPherson, G. C., Ramsay, C. R., & Campbell, M. K. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00242-8 · Cited by 651 · cited 1×
“investigators at the time of obtaining consent from prospective trial participants [18].”
BackgroundA brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Moher, D., Fortin, P., Jadad, A. R., Jüni, P., Klassen, T., Le Lorier, J., Liberati, A., Penna, A., & Linde, K. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90538-3 · Cited by 537
Godwin, M., Ruhland, L., Casson, I., MacDonald, S., Delva, D., Birtwhistle, R., Lam, M., & Seguin, R. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-28 · Cited by 506
Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies
Smith, R. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020138 · Cited by 498
Differential dropout and bias in randomised controlled trials: when it matters and when it may not
Bell, M. L., Kenward, M. G., Fairclough, D. L., & Horton, N. J. (2013) · BMJ · doi:10.1136/bmj.e8668 · Cited by 460
On the distinction between interaction and effect modification
VanderWeele, T. J. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181ba333c · Cited by 450
Berkson's Bias, Selection Bias, and Missing Data
Westreich, D. (2012) · Epidemiology · doi:10.1097/ede.0b013e31823b6296 · Cited by 322
MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
Siddiqui, O., Hung, H. M. J., & O'Neill, R. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400802609797 · Cited by 301 · cited 15×
“usually less biased by missing data compared with LOCF [41].”
ResultInfluentialCommon pitfalls in statistical analysis: Intention-to-treat versus per-protocol analysis
Ranganathan, P., Pramesh, C., & Aggarwal, R. (2016) · Perspectives in Clinical Research · doi:10.4103/2229-3485.184823 · Cited by 296 · cited 1×
“the number of exclusions increases [31].”
Criteria for Distinguishing Effectiveness From Efficacy Trials in Systematic Reviews
Gartlehner, G., Hansen, R. A., Nissman, D., Lohr, K. N., & Carey, T. S. (2006) · Cited by 280
A Model of Placebo Response in Antidepressant Clinical Trials
Rutherford, B. R., & Roose, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040474 · Cited by 268
Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches
Lane, P. (2008) · Pharmaceutical Statistics · doi:10.1002/pst.267 · Cited by 262 · cited 1×
“bias for the case involving missing at nonrandom dropouts [42].”
BackgroundEffectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?
Ioannidis, J. P. (2008) · Philosophy, Ethics, and Humanities in Medicine · doi:10.1186/1747-5341-3-14 · Cited by 253 · cited 3×
“In the United States, 73.6% of patients receive antidepressants from their general medical provider rather than from a psychiatrist.”
MethodInfluentialEmerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
Selective Reporting Biases in Cancer Prognostic Factor Studies
Kyzas, P. A., Loizou, K. T., & Ioannidis, J. P. A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji184 · Cited by 231
Wisniewski, S. R., Rush, A. J., Nierenberg, A. A., Gaynes, B. N., Warden, D., Luther, J. F., McGrath, P. J., Lavori, P. W., Thase, M. E., Fava, M., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071027 · Cited by 223 · cited 14×
“One of the authors was involved in a multicenter DBRPCT about a decade ago.”
MethodInfluentialHow evidence‐based medicine is failing due to biased trials and selective publication
Every‐Palmer, S., & Howick, J. (2014) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12147 · Cited by 223
Investigating patient exclusion bias in meta-analysis
Tierney, J. F. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh300 · Cited by 221 · cited 1×
“A meta-analyses, of individual patient data, showed that beneficial effects of an experimental treatment was higher in studies having patient exclusions than analyses based on all or most patients randomized [22].”
MethodMojtabai, R., & Olfson, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0704 · Cited by 185
Trends in the Development of New Antidepressants. Is there a Light at the End of the Tunnel?
Pacher, P., & Kecskemeti, V. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043455594 · Cited by 175
Quantitative analysis of sponsorship bias in economic studies of antidepressants
Baker, C. B., Johnsrud, M. T., Crismon, M. L., Rosenheck, R. A., & Woods, S. W. (2003) · British Journal of Psychiatry · doi:10.1192/03-2 · Cited by 171
Bias, Confounding, and Interaction: Lions and Tigers, and Bears, Oh My!
Vetter, T. R., & Mascha, E. J. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002332 · Cited by 170
The physician's actions and the outcome of illness in family practice.
Bass, M. J., Buck, C., Turner, L., Dickie, G. L., Pratt, G. A., & Robinson, H. (1986) · PubMed · Cited by 167
Antidepressants and the placebo effect
Kirsch, I. (2014) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000176 · Cited by 164 · cited 1×
“However, if a clinical trial is large enough, even less difference in HAM-D may produce statistical significance of antidepressant over placebo [54].”
BackgroundAn Overview of Practical Approaches for Handling Missing Data in Clinical Trials
DeSouza, C. M., Legedza, A. T. R., & Sankoh, A. J. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400903242795 · Cited by 143
Sensitivity of the six‐item Hamilton Depression Rating Scale
O'Sullivan, R. L., Fava, M., Agustin, C., Baer, L., & Rosenbaum, J. F. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09649.x · Cited by 141
A Review of Current Guidelines for Depression Treatment
Gelenberg, A. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9078tx1c · Cited by 137
Mechanisms Involved in Placebo and Nocebo Responses and Implications for Drug Trials
Rief, W., Bingel, U., Schedlowski, M., & Enck, P. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.204 · Cited by 134
Siddiqui, O., & Ali, M. W. (1998) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409808835259 · Cited by 133
Rating scales in depression: limitations and pitfalls
Bech, P. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/pbech · Cited by 129
Validity of Clinical Trials of Antidepressants
Quitkin, F. M., Rabkin, J. G., Gerald, J., Davis, J. M., & Klein, D. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.3.327 · Cited by 117
What is publication bias in a meta-analysis?
Sedgwick, P. (2015) · BMJ · doi:10.1136/bmj.h4419 · Cited by 101
COMPARISON OF ALTERNATIVE STRATEGIES FOR ANALYSIS OF LONGITUDINAL TRIALS WITH DROPOUTS
Liu, G., & Gould, A. L. (2002) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-120015744 · Cited by 101
Nutt, D., & Goodwin, G. M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.05.004 · Cited by 99
NICE guidelines for the management of depression
Middleton, H., Shaw, I., Hull, S., & Feder, G. (2005) · BMJ · doi:10.1136/bmj.330.7486.267 · Cited by 93
Iannuzzo, R. W., Jaeger, J., Goldberg, J. F., Kafantaris, V., & Sublette, M. E. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.10.009 · Cited by 90
Intention to treat analysis versus per protocol analysis of trial data
Sedgwick, P. (2015) · BMJ · doi:10.1136/bmj.h681 · Cited by 90
“Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?
Eichler, H., Bloechl‐Daum, B., Bauer, P., Bretz, F., Brown, J. S., Hampson, L., Honig, P. K., Krams, M., Leufkens, H. G. M., Lim, R. R., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.515 · Cited by 85
Mahableshwarkar, A. R., Jacobsen, P. L., Serenko, M., Chen, Y., & Trivedi, M. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09337 · Cited by 84 · cited 1×
“hypomanic episode, schizophrenia, or substance abuse disorder’ [10,11].”
BackgroundDavidson, O. B., & Eden, D. (2000) · Journal of Applied Psychology · doi:10.1037//0021-9010.85.3.386 · Cited by 81
Contribution of spontaneous improvement to placebo response in depression: A meta-analytic review
Rutherford, B. R., Mori, S., Sneed, J. R., Pimontel, M. A., & Roose, S. P. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.02.008 · Cited by 79
Kisely, S., Scott, A., Denney, J., & Simon, G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.019869 · Cited by 77
Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000057 · Cited by 77
The Use of Placebo in Clinical Trials on Bipolar Disorder: A New Approach for an Old Debate
Vieta, E., & Carné, X. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000082021 · Cited by 70
The role of nonrandomized trials in the evaluation of oncology drugs
Simon, R. M., Blumenthal, G., Rothenberg, M. L., Sommer, J., Roberts, S., Armstrong, D. K., LaVange, L. M., & Pazdur, R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.86 · Cited by 70
Regression toward the Mean: Its Etiology, Diagnosis, and Treatment
Streiner, D. V. L. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600111 · Cited by 63
Commentary: Berkson's Bias reviewed
Schwartzbaum, J., Ahlbom, A., & Feychting, M. (2003) · European Journal of Epidemiology · doi:10.1023/b:ejep.0000006552.89605.c8 · Cited by 62
Anxiety and depression: individual entities or two sides of the same coin?
Nutt, D. (2004) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500410005513 · Cited by 61
The impact of analytic method on interpretation of outcomes in longitudinal clinical trials
Prakash, A., Risser, R. C., & Mallinckrodt, C. H. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01808.x · Cited by 59 · cited 1×
“In contrast to LOCF, MMRM uses the actual data from all patients to predict what would have happened if the dropped out patients had actually stayed in the trial [40].”
MethodMissing data and the trouble with LOCF
Streiner, D. L. (2008) · Evidence Based Mental Health · doi:10.1136/ebmh.11.1.3-a · Cited by 59
The Role of Patient Expectancy in Placebo and Nocebo Effects in Antidepressant Trials
Rutherford, B. R., Wall, M. M., Glass, A., & Stewart, J. W. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08797 · Cited by 58
Evaluating solutions to sponsorship bias
Doucet, M., & Sismondo, S. (2008) · Journal of Medical Ethics · doi:10.1136/jme.2007.022467 · Cited by 57
Commentary: Empirical evidence of attrition bias in clinical trials
Jüni, P., & Egger, M. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh406 · Cited by 56
Clinical Trials and the Real World: Selection Bias and Generalisability of Trial Results
Sharpe, N. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1015327801114 · Cited by 55
The effect of antidepressants on fertility
Casilla-Lennon, M., Meltzer-Brody, S. E., & Steiner, A. Z. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.01.170 · Cited by 53
Woolley, S. B., Cardoni, A. A., & Goethe, J. W. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.12.1408 · Cited by 52 · cited 1×
“domized antidepressant efficacy trials published over a 40year period from 1965 to 2004 showed that more than 352 trials were conducted using LOCF methods [39].”
MethodRutherford, B. R., Sneed, J. R., Tandler, J. M., Rindskopf, D., Peterson, B. S., & Roose, S. P. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.04.004 · Cited by 51
Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression
Isacsson, G., & Adler, M. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01815.x · Cited by 40
Boessen, R., Groenwold, R. H. H., Knol, M. J., Grobbee, D. E., & Roes, K. C. B. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.08.026 · Cited by 40
Bschor, T., & Kilarski, L. L. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1155985 · Cited by 38
The Intention-to-Treat Analysis Is Not Always the Conservative Approach
Shrier, I., Verhagen, E. A. L. M., & Stovitz, S. D. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.023 · Cited by 36
Cristea, I. A., Gentili, C., Pietrini, P., & Cuijpers, P. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.179275 · Cited by 34
Stettin, G., Yao, J., Verbrugge, R. R., & Aubert, R. E. (2006) · PubMed · Cited by 31
Predictors of placebo response in bipolar depression
Nierenberg, A. A., Østergaard, S. D., Iovieno, N., Walker, R. S. W., Fava, M., & Papakostas, G. I. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000058 · Cited by 24
Expectancy Effect in Three Mind-Body Clinical Trials
Hicks, M., Hanes, D. A., & Wahbeh, H. (2016) · Journal of Evidence-Based Complementary & Alternative Medicine · doi:10.1177/2156587216652572 · Cited by 17
Abdin, E., Vaingankar, J. A., Picco, L., Seow, E., Chua, B. Y., Ng, L. L., Mahendran, R., Chua, H. C., Heng, D., & Chong, S. A. (2017) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v46n3p91 · Cited by 17
Bruyère, O., Kanis, J. А., Ibar-Abadie, M.-E., Alsayed, N., Brandi, M. L., Burlet, N., Cahall, D. L., Chines, A. A., Devogelaer, J.-P., Dere, W. H., et al. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1190-9 · Cited by 13
The placebo arm in clinical studies for treatment of Psychiatric Disorders: A Regulatory Dilemma
Wied, C. C. G., Stoyanova, V., Yu, Y., Isaac, M., Pani, L., & Andres-Trelles, F. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.007 · Cited by 12
Streiner, D. L. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000551 · Cited by 12
The funding crisis in psychopharmacology: an historical perspective
Hendrie, C. A. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108100253 · Cited by 9
The Halo Effect: An Unintended Benefit of Care Pathways
Barber, C., Fraser, J., Mendez, G., Bradley, B., Loftus, T., & Jacofsky, D. (2016) · The Journal of Knee Surgery · doi:10.1055/s-0036-1584577 · Cited by 9
Wyer, P. C., & da Silva, S. A. (2015) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12330 · Cited by 8
The “Pygmalion Effect” and Surgical Mentoring
John, M. M. (2016) · Indian Journal of Surgery · doi:10.1007/s12262-015-1432-3 · Cited by 8
Ellis, A., Dusetzina, S., Hansen, R., Gaynes, B., Farley, J., & Stürmer, T. (2013) · Annals of Epidemiology · doi:10.1016/j.annepidem.2013.01.004 · Cited by 7
McGoldrick, R., Hui, K., & Chang, J. (2014) · Hand Clinics · doi:10.1016/j.hcl.2014.04.004 · Cited by 7
The Use of Placebos in Clinical Trials and Clinical Practice
Kirsch, I. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600401 · Cited by 6
Drug promotion tactics-yet another pharma deception?
Tagore, A. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12204 · Cited by 6
Helms, R. W. (2016) · Pharmaceutical Statistics · doi:10.1002/pst.1767 · Cited by 4
Efficacy of Antidepressants: Issues Related to Bias in Clinical Trials
Spina, E. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.07.017 · Cited by 1
Research works printed but not linked: 6
- 10.1192/bjp.183.6.498 · doi:10.1192/bjp.183.6.498 · Paper page
- Kirsch I, 2014, Z Psychol, 222, 128
- 10.1037/0021-9010.85.3.386 · doi:10.1037/0021-9010.85.3.386 · Paper page
- Stettin GD, 2006, Am J Manag Care, 12, 453
- Bass MJ, 1986, J Fam Pract, 23, 43
- Friedman JH, 2004, Med Health R I, 87, 262
Cited by
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01520-y · Cited by 408
“Although SSRIs and serotonin-norepinephrine reuptake inhibitor perform better than placebo at reducing symptoms of depression [187, 188], there are weeks-long lag time in attaining Untreated Depression Treated Depression”
BackgroundAddressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299
“Various biases could have resulted in discrepancies between results from RCT and naturalistic studies.(105) An interesting meta-analysis compared reports of adverse effects in the placebo groups in SSRIs and TCAs among RCTs.”
BackgroundResultSelf-citationBraslow, J. T., & Marder, S. R. (2019) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050718-095514 · Cited by 122
Hengartner, M. P., & Plöderl, M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00517 · Cited by 93
The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank
Wong, W. L. E., Fabbri, C., Laplace, B., Li, D., van Westrhenen, R., Lewis, C. M., Dawe, G. S., & Young, A. H. (2023) · Pharmaceuticals · doi:10.3390/ph16091277 · Cited by 43
Metadata
- Authors
- Wang, S.-M., Han, C., Lee, S.-J., Jun, T.-Y., Patkar, A. A., Masand, P. S., & Pae, C.-U.
- Affiliations
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Korea University (KR)
- Catholic University of Korea (KR)
- Duke Medical Center (US)
- Global Medical Education, New York, NY, USA
- Corresponding author
- Pae, Chi-Un
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2017-09-14
- Volume
- 11
- Issue
- 1
- Pages
- 15-25
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2754151110
- Cited by
- 20
- References
- 91
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 2 · 2019: 7 · 2018: 3
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) (HC15C1405)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- antidepressants, antidepressant efficacy, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, major depressive disorder, trial bias, placebo response, publication bias, sponsorship bias, university-industry collaboration, clinical trial failure, psychiatric drug development
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Antidepressive Agents, Major Depressive Disorder, Humans, Bias, Placebo Effect, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Publication Bias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.